These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 24177758)

  • 1. Response to neoadjuvant chemotherapy in ductal compared to lobular carcinoma of the breast: a meta-analysis of published trials including 1,764 lobular breast cancer.
    Petrelli F; Barni S
    Breast Cancer Res Treat; 2013 Nov; 142(2):227-35. PubMed ID: 24177758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences in sensitivity to neoadjuvant chemotherapy among invasive lobular and ductal carcinoma of the breast and implications on surgery-A systematic review and meta-analysis.
    O'Connor DJ; Davey MG; Barkley LR; Kerin MJ
    Breast; 2022 Feb; 61():1-10. PubMed ID: 34864494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in Response and Surgical Management with Neoadjuvant Chemotherapy in Invasive Lobular Versus Ductal Breast Cancer.
    Truin W; Vugts G; Roumen RM; Maaskant-Braat AJ; Nieuwenhuijzen GA; van der Heiden-van der Loo M; Tjan-Heijnen VC; Voogd AC
    Ann Surg Oncol; 2016 Jan; 23(1):51-7. PubMed ID: 25980321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma.
    Cocquyt VF; Blondeel PN; Depypere HT; Praet MM; Schelfhout VR; Silva OE; Hurley J; Serreyn RF; Daems KK; Van Belle SJ
    Eur J Surg Oncol; 2003 May; 29(4):361-7. PubMed ID: 12711290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas.
    Delpech Y; Coutant C; Hsu L; Barranger E; Iwamoto T; Barcenas CH; Hortobagyi GN; Rouzier R; Esteva FJ; Pusztai L
    Br J Cancer; 2013 Feb; 108(2):285-91. PubMed ID: 23299541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer.
    Lips EH; Mukhtar RA; Yau C; de Ronde JJ; Livasy C; Carey LA; Loo CE; Vrancken-Peeters MJ; Sonke GS; Berry DA; Van't Veer LJ; Esserman LJ; Wesseling J; Rodenhuis S; Shelley Hwang E;
    Breast Cancer Res Treat; 2012 Nov; 136(1):35-43. PubMed ID: 22961065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Invasive ductal carcinoma and invasive lobular carcinoma of breast differ in response following neoadjuvant therapy with epidoxorubicin and docetaxel + G-CSF.
    Wenzel C; Bartsch R; Hussian D; Pluschnig U; Altorjai G; Zielinski CC; Lang A; Haid A; Jakesz R; Gnant M; Steger GG
    Breast Cancer Res Treat; 2007 Jul; 104(1):109-14. PubMed ID: 17061042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile.
    Mathieu MC; Rouzier R; Llombart-Cussac A; Sideris L; Koscielny S; Travagli JP; Contesso G; Delaloge S; Spielmann M
    Eur J Cancer; 2004 Feb; 40(3):342-51. PubMed ID: 14746851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast.
    Marmor S; Hui JYC; Huang JL; Kizy S; Beckwith H; Blaes AH; Rueth NM; Tuttle TM
    Cancer; 2017 Aug; 123(16):3015-3021. PubMed ID: 28382636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patients with invasive lobular breast cancer are less likely to undergo breast-conserving surgery: a population based study in the Netherlands.
    Truin W; Roumen RM; Siesling S; van der Heiden-van der Loo M; Duijm LE; Tjan-Heijnen VC; Voogd AC
    Ann Surg Oncol; 2015 May; 22(5):1471-8. PubMed ID: 25323475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor-Positive, HER2 Negative Patients Likely to Benefit from Neoadjuvant Chemotherapy.
    Petruolo OA; Pilewskie M; Patil S; Barrio AV; Stempel M; Wen HY; Morrow M
    Ann Surg Oncol; 2017 Sep; 24(9):2556-2562. PubMed ID: 28560596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breast surgery after neoadjuvant chemotherapy in patients with lobular carcinoma: surgical and oncologic outcome.
    van Hemert A; van Loevezijn AA; Bosman A; Vlahu CA; Loo CE; Peeters MTFDV; van Duijnhoven FH; van der Ploeg IMC
    Breast Cancer Res Treat; 2024 Apr; 204(3):497-507. PubMed ID: 38189904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncologic safety of breast-conserving surgery compared to mastectomy in patients receiving neoadjuvant chemotherapy for locally advanced breast cancer.
    Cho JH; Park JM; Park HS; Park S; Kim SI; Park BW
    J Surg Oncol; 2013 Dec; 108(8):531-6. PubMed ID: 24115142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful Breast Conservation After Neoadjuvant Chemotherapy in Lobular Breast Cancer: The Role of Menopausal Status in Response to Treatment.
    Ramalingam K; Clelland E; Rothschild H; Mujir F; Record H; Kaur M; Mukhtar RA
    Ann Surg Oncol; 2023 Nov; 30(12):7099-7106. PubMed ID: 37561345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution.
    Tubiana-Hulin M; Stevens D; Lasry S; Guinebretière JM; Bouita L; Cohen-Solal C; Cherel P; Rouëssé J
    Ann Oncol; 2006 Aug; 17(8):1228-33. PubMed ID: 16740599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rate of re-excision after breast-conserving surgery for invasive lobular carcinoma.
    Wanis ML; Wong JA; Rodriguez S; Wong JM; Jabo B; Ashok A; Lum SS; Solomon NL; Reeves ME; Garberoglio CA; Senthil M
    Am Surg; 2013 Oct; 79(10):1119-22. PubMed ID: 24160812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of oncoplastic breast surgery in the management of breast cancer treated with primary chemotherapy.
    Mazouni C; Naveau A; Kane A; Dunant A; Garbay JR; Leymarie N; Sarfati B; Delaloge S; Rimareix F
    Breast; 2013 Dec; 22(6):1189-93. PubMed ID: 24054903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Single-Agent Chemotherapy for Patients with Advanced Invasive Lobular Carcinoma: A Pooled Analysis from Three Clinical Trials.
    Pérez-Garcia J; Cortés J; Metzger Filho O
    Oncologist; 2019 Aug; 24(8):1041-1047. PubMed ID: 30578311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial.
    Olson JA; Budd GT; Carey LA; Harris LA; Esserman LJ; Fleming GF; Marcom PK; Leight GS; Giuntoli T; Commean P; Bae K; Luo J; Ellis MJ
    J Am Coll Surg; 2009 May; 208(5):906-14; discussion 915-6. PubMed ID: 19476859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do non-classic invasive lobular carcinomas derive a benefit from neoadjuvant chemotherapy?
    Mamtani A; Grabenstetter A; Sevilimedu V; Morrow M; Gemignani ML
    Breast Cancer Res Treat; 2023 Jan; 197(2):417-423. PubMed ID: 36394689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.